Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer-Reference-Cited by-同舟云学术

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Published:2017-09-04 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Jacobsen Kirstine,Bertran-Alamillo Jordi,Molina Miguel Angel,Teixidó Cristina,Karachaliou Niki,Pedersen Martin Haar,Castellví Josep,Garzón Mónica,Codony-Servat Carles,Codony-Servat Jordi,Giménez-Capitán Ana,Drozdowskyj Ana,Viteri Santiago,Larsen Martin R.,Lassen Ulrik,Felip Enriqueta,Bivona Trever G.,Ditzel Henrik J.^ORCID,Rosell Rafael

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-017-00450-6.pdf

Reference52 articles.

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).

2. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).

3. Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121–128 (2010).

4. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).

5. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735–742 (2011).

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds;Cell Communication and Signaling;2024-07-26

2. PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC;Clinical Cancer Research;2024-07-17

3. Identifying potential risk genes for clear cell renal cell carcinoma with deep reinforcement learning;2024-06-23

4. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma;Cancer Cell International;2024-06-13

5. Low-frequency ERK and Akt activity dynamics are predictive of stochastic cell division events;npj Systems Biology and Applications;2024-06-04